|
|
Title:
Using viruses to detect or purify proteins
United States Patent: 7,670,801
Issued: March 2, 2010
Inventors: Gleba; Yuri (Munchen,
DE), Bascomb; Newell (Wayne, NJ), Negrouk; Valentin (Plainsboro, NJ)
Assignee: Icon Genetics,
Inc. (Princeton, NJ)
Appl. No.: 10/466,291
Filed: January 18, 2002
PCT Filed: January 18, 2002
PCT No.: PCT/US02/01676
371(c)(1),(2),(4) Date: July
15, 2003
PCT Pub. No.: WO02/068927
PCT Pub. Date: September
06, 2002
|
|
|
George Washington University's Healthcare MBA
|
Abstract
Disclosed are methods of isolating and
purifying proteins and other organic small molecules produced in hosts
using viruses. Also disclosed are methods of visualizing and/or localizing
proteins and other organic small molecules produced in hosts using
viruses. Further disclosed are compositions of matter containing the
protein or small molecule bound to a virus.
Description of the
Invention
TECHNICAL FIELD
The present invention relates to the use of viruses to detect or isolate
proteins and small molecules from hosts in which they are produced.
BACKGROUND ART
During the last several years, significant progress was made in
utilization of transgenic plants and other living organisms for production
of industrial oils, plastics, edible vaccines and industrially important
recombinant proteins. In two latter cases, it was found that plants are
able to produce high levels of safe, functional, recombinant proteins and
can be easily expanded to agricultural levels to meet industrial demands
(Fischer et al., 1999 a, b). Current applications of plants,
microorganisms and animal cells in biotechnology include the production of
hormones, enzymes, antibodies, plasma proteins, cytokines and vaccines.
Recombinant proteins can be produced either by genetically inherited
expression in transgenic plants or by transient expression in
virus-infected plants.
A revolutionary breakthrough in large-scale production of recombinant
proteins in plants was made several years ago by using plant RNA viruses (Kumagai
et al., 1993; Hamamoto et al., 1993). The principle of all RNA viral
expression systems is the same: upon inoculation, viral RNA replicates in
the cytoplasm to high copy number, and the viral progeny RNA is translated
resulting in the expression of virally encoded proteins. The virus moves
systemically through the whole plant by cell-to-cell and long-distance
movement. For vector construction, viral RNA genomes are
reverse-transcribed in vitro and cloned as full-length cDNAs in
transcription vectors in vitro or in vivo (Boyer, Haenni, 1994). The
cloned viral genomes can then be manipulated with standard DNA techniques.
For inoculation of plants, recombinant viral vectors are usually
transcribed in vitro and the synthesized RNA is inoculated mechanically
onto plants by gently rubbing the leaves with a mild abrasive. Extracts
from these infected plants can also be used for the subsequent inoculation
of very large numbers of plants. One of the most efficient transient
expression viral vectors is tobacco mosaic virus (TMV)-based hybrid
vectors that contain a heterologous coat protein subgenomic mRNA promoter
and coat protein open reading frame and either TMV or heterologous 3'
non-translated region (Shivprasad et al, 1999). The size of the gene that
can be expressed with viral vector usually does not exceed 2 kb.
A comparison of features of recombinant protein production in plants,
yeast, bacterial, and animal systems is presented in Fischer et al, (1999
a, b). Both transgenic plants and plant viral systems have many advantages
compared to the yeast, bacterial, and animal systems. One of the most
impressive advantages of the recombinant protein production in plants is
the cost of production. The production of proteins from plants infected
with viral vectors is several times lower compared to stable transformed
transgenic plants. In addition, the time required for the creation of a
new plant viral vector product is significantly lower compared to
transgenic plants. This low cost and high speed turnaround time are
especially important for biotechnological companies. According to data
presented by Large Scale Biology (formerly Biosource), the time required
to go from a gene expression feasibility study to greenhouse and/or pilot
field production, to recovery and purification into purified protein
product takes about a year. For transgenic plants it would take at least
three years under ideal circumstances. Viral RNA vector systems can be
used for the production of different proteins and polypeptides ranging in
mass from 4 kd to about 70 kd.
Small epitopic oligopeptides (e.g., less than 25 amino acids in length)
can also be produced on the surface of viral particles by gene-fusions
created with coat-protein genes (Hamamoto et al., 1993; Fitchen et al.,
1995; McLain et al., 1995; Yusibov et al., 1997; Johnson et al., 1997; Koo
et al., 1999). There are significant data demonstrating that epitopic
oligopeptides on the surface of TMV or other plant viruses induce a strong
immune response in vaccinated animals.
On the other hand, for proteins or molecules requiring a high degree of
purity, downstream processing from plant biomass is assumed to be
generally more problematic and expensive. As a rule, the recombinant
product constitutes only a minor fraction of the total biomass. It is well
known that in microbial production systems that have been optimized with
regard to product yield, up to 90% of total production costs are the costs
related to purification of the molecule of interest from the host, rather
than expenses of the production itself To make the production from
transgenic plants economical, strategies are needed that will allow rapid
and inexpensive separation of the recombinant or endogenous proteins of
interest or non-proteinaceous small molecules, from other endogenous plant
molecules. Since most efficient purification platforms are based on
specific affinity between the molecule of interest and the purification
matrix, the problem is best addressed by developing a simple and
inexpensive high-affinity matrix that can than be used to specifically
bind the molecule of interest. One such matrix contemplated in this
invention is a protein surface of a virus particle.
The size and biochemical characteristics of every protein are different,
so the method of purification must be different for different proteins.
One of the approaches that would have a general applicability is the use
of separation techniques to concentrate and purify the protein by
affinity-mediated isolation. As in microbial systems, expression of the
proteins as fusion products (i.e., having an affinity tag) would also
facilitate the use of affinity isolation for recovery from plant extracts.
There are a number of different commercially available fusion tags for
bacterial and animal systems. At least some of them might work in plants;
however, they are too expensive for large-scale production.
Ideal characteristics of an ideal affinity tag-based purification system
include a homogenous, inexpensive, uniform and specific molecular surface
which itself can form large stable aggregates with mass significantly
greater than 200-300 kd. This aggregate should bear affinity tags on its
surface strong enough to be bound by the protein of interest and to purify
it by precipitation. The complex with the protein of interest should in
turn, be easy to dissociate under relatively mild ionic conditions.
Ideally the affinity matrix would be reusable. Such a system could be used
not only in plant biotechnology but also for protein purification in
bacterial and animal biotechnology.
SUMMARY OF THE INVENTION
Applicants have invented methods for the purification or visualization of
proteins or small molecules using viruses. The method is applicable to a
wide variety of protein expression systems including plants, animals and
bacteria.
A first aspect of the present invention is directed to a method of
purifying a protein or non-proteinaceous small molecule of interest. The
method entails: (a) providing a virus having on its surface at least one
recognition peptide. The recognition peptide may be present as a
sub-sequence on the surface of (one of) the viral coat protein(s).
Alternatively, a viral expression vector is provided, wherein the vector
will direct re-assembly of particles of the virus in an organism or cells
thereof (e.g., the host). The method also involves (b) obtaining a host
that produces the protein or small molecule of interest independent from
or due to presence of the virus therein. The protein or small molecule may
be produced endogenously by the host or exogenously as a result of the
presence of one or more transgenes introduced into the host by way the
viral expression vector or via a transformation event with a distinct
nucleic acid vector. The virus is caused to come into contact with the
protein or small molecule in order to bind (e.g., form a complex)
therewith. This can be achieved by infecting the host with the virus or
the viral expression vector, followed by harvesting the complexes of the
virus and protein from the host. Alternatively, a lysate of the host or
another type of solution (e.g., homogenate) of the host (and which
contains the protein) may be prepared. The protein can be isolated from
the solution by contacting the solution with the virus e.g., absorbed on
an affinity matrix such as a column. The binding of the virus with the
protein or small molecule may be direct or indirect in the sense that the
virus may have affinity for the protein per se, or for a fusion partner
that is co-expressed with the protein. The recognition peptide may be
endogenous to the virus (i.e., present in a naturally occurring wild-type
or mutant) virus or can be the result of a genetic modification to a virus
whereby an affinity or recognition peptide is integrated into a surface of
a coat protein of the virus. The virus particles having the protein or
small molecule of interest bound thereto are harvested, whereupon the
virus and protein may be dissociated from one another.
In various preferred embodiments, the host is a transgenic plant such as
nicotiana, brassica, arabidopsis, soybean, wheat, pearl millet or maize;
the virus is tobacco mosaic virus (TMV), Bean Golden Mosaic Virus, an
adenovirus, baculovirus or a phage e.g., T even and T odd phage; the
protein is expressed in the form of a fusion protein, and the cleavable
linkage between the protein and its fusion partner is an enterokinase or
cyanogen bromide site; and the virus and fusion protein are brought into
contact by infecting the plant with a vector containing the viral nucleic
acid (e.g., a plant, animal, bacterial or yeast viral vector). The fusion
partner, which is a peptide having affinity for a recognition sequence on
a virus, is a single chain fragment of an antibody or an antibody, and the
recognition sequence is non-native to the virus such as a polyhistidine or
a FLAG peptide. Hence, a preferred embodiment in accordance with this
aspect of the present invention is directed to method of production and
purification of an exogenous protein produced in a plant host. The method
involves (a) providing a plant virus containing a coat protein, wherein a
surface of the coat protein contains a recognition peptide (more
preferably one which is non-native to the virus), or in the alternative
providing a (recombinant) viral expression vector or pro-vector which upon
expression in a cell of the plant host yields particles of the virus. The
host is genetically modified with one or more transgenes to produce the
protein of interest (and more preferably to produce the protein in the
form of a fusion wherein the peptide linked to the protein binds the
recognition peptide on the viral surface. The virus particles are caused
to come into contact with the protein. This contact is achieved by
infecting the host with the virus, introducing the viral expression vector
into the host followed by harvesting the complexes of virus and protein
from the host. Alternatively, a lysate or solution (e.g., homogenate)
obtained from the plant host and that contains the protein is contacted
with the virus, preferably immobilized on a matrix such as a column,
whereby particles of the virus bind (e.g., form complexes) with the
protein and separate the protein from the lysate or solution. Then, the
protein can be dissociated from the virus.
Another preferred embodiment in accordance with this aspect of the present
invention is directed to a method for isolating an endogenous protein from
a plant host. The method involves (a) providing a plant virus containing a
coat protein, wherein a surface of the coat protein contains a recognition
peptide (more preferably one which is non-native to the virus), or in the
alternative providing a (recombinant) viral expression vector or
pro-vector which upon expression in a cell of the plant host yields
particles of the virus. The host is cultured so as to cause production of
the protein. The virus particles are caused to come into contact with the
protein. This contact is achieved by infecting the host with the virus,
introducing the viral expression vector into the host, followed by
harvesting the complexes of the virus and protein. Alteratively, a lysate
or solution (e.g., homogenate) obtained from the plant host and that
contains the protein is contacted with the virus which is preferably
immobilized on a matrix such as a column, whereby particles of the virus
bind (e.g., form complexes) with the protein, and separate the protein
from the lysate or solution. Then, the protein can be dissociated from the
virus. A preferred protein is streptavidin.
A further aspect of the present invention is directed to a method of
visualizing or localizing a protein or non-proteinaceous small molecule of
interest. The method entails (a) providing a virus having affinity for the
protein or small molecule and an affinity for a visualization agent; (b)
obtaining a host that produces the protein or small molecule of interest;
(c) contacting the host or a preparation thereof with the virus; (d)
exposing the thus-contacted host or preparation thereof with the
visualization agent; and (e) detecting presence or locale of the protein
or small molecule.
Yet a further aspect of the present invention is directed to compositions.
One such composition is directed to a non-human host containing virus
particles having on their surfaces a recognition peptide, the particles
having a protein or non-proteinaceous small molecule bound thereto
directly or indirectly via the recognition peptide. Another composition is
directed to virus particles having on their surfaces a recognition
peptide, the particles having a protein or non-proteinaceous small
molecule of interest bound thereto directly or indirectly via the
recognition peptide. The compositions may further contain a visualization
agent such as a detectable label attached to or otherwise associated with
the virus (e.g., such as by way of another recognition peptide). These
compositions are formed during the course of practicing the methods of the
present invention.
The methods and compositions of the present invention take advantage of a
virus as an easily programmable and self-replicating biological affinity
matrix that can be introduced into a living biological system or an
extract thereof, to isolate and purify or otherwise detect, visualize or
locate proteins or small molecules, rapidly and inexpensively.
BEST MODE OF CARRYING OUT INVENTION
The present invention utilizes various properties of viruses for the
purposes of purifying or visualizing proteins produced in hosts (which for
purposes of this invention is meant to include any biological protein
production facility other than a human being). In particular, it utilizes
the protein surface of viral particles as a high-affinity ligand and the
relatively high molecular weight of virus particles, to develop simple
procedures for separation complexes that form between the virus and a
protein of interest from other molecules, and in particular separation
from proteins and small molecules whose molecular weight is much lower
than the weight of the complex of virus and the molecule of interest.
Viruses, whether naturally occurring wild-type or mutant viruses, or
genetically engineered in nature, are self-replicating "machines" and as
such, are very inexpensive. Viruses are also much larger than the great
majority of proteins or small molecules for which purification procedures
are required. The great difference in weight or in physico-chemical
properties can be effectively exploited to separate the molecule of
interest from the mixture, such as tissue homogenate, by binding the
molecule of interest to a virus particle and then separating the resultant
complex from the rest of the mixture. The association between the viral
particle and the molecule of interest can later be dissolved in a number
of ways known to those skilled in the art of affinity chromatography.
A virus usually has an envelope composed of repeats of one or a small
number of so-called coat protein molecules. Thus, the surface of virus is
a repetition of monomers displaying polypeptide motifs with very well
defined structure. One skilled in the art is able to design a ligand that
recognizes a specific viral surface motif and binds to a wild type virus.
Such recognition peptide(s) may also be integrated into the viral surface
by genetically modifying the coat protein structure of the virus so as to
design a specific surface with specific affinity properties. In
embodiments of the invention utilizing a virus having more than one coat
protein and which require multiple recognition peptides, they may be
present on the same or different coat proteins. The site and composition
of the recognition peptide(s) are selected so as not to interfere with
virus infection, replication, assembly or spreading. Since viruses are
usually present in multiple copies in a cell or in purified preparations,
they can be used as a natural affinity column.
The invention may be used to purify the proteins or other molecules that
are small comparing to the viral particle itself. In the preferred
embodiment, the invention is used to separate proteins. In the most
preferred embodiment, the invention is used to separate proteins produced
by wild-type or genetically engineered or transgenic organisms. For the
purposes of the present invention, the virus may be multiplied in a cell
that is also the production host, or it may be produced in another
organism, in which case the virus and the molecule of interest are then
brought into contact such as by mixing homogenates or lysates of the
production host (e.g., organism or tissues or cells thereof) with
purified/unpurified virus. In one embodiment of the present invention, the
virus is engineered to serve both as an expression vector for the protein
of interest and as an affinity ligand for that protein. Preferred
embodiments entail the use of plant viruses but the method may be
practiced with any virus, such as but not limited to, plant virus, animal
virus, fungal virus, bacteriophage, or genetically engineered or synthetic
replicons having properties described above. Likewise, the method may be
practiced using a wide variety of host expression systems including plants
(including cell and tissue cultures thereof), animals including non-human
animal organisms, and animal and human cell cultures, fungi, bacteria and
yeast.
The present method of purifying proteins or small molecules can be
practiced in many different ways depending on several factors such as the
nature of the protein relative to the host and the manner in which the
protein is produced in the host and the nature of the affinity between the
virus and the protein. In embodiments where the protein or small molecule
is produced endogenously by the host, the method is practiced relatively
simply. The host is cultured and lysed. The lysate or a more refined
solution containing the protein is contacted with the virus. The virus can
be immobilized on a matrix such as a column. Alternatively, the host may
be infected by the virus (which might have been propagated in an organism
that is not the host) or a viral replication vector such that intact virus
particles form in the infected host. Purification of proteins that are not
produced endogenously by the host requires a genetic manipulation in order
to supply the host with the machinery i.e., at least one transgene that
encodes or otherwise directs expression of the protein. In these
embodiments, the transgene(s) may be introduced into the host as part of
the viral expression/replication vector, or via a separate transformation
event. The affinity of the virus for the protein may be direct or indirect
in the sense that the transgene may encode the protein in the form of a
fusion with a binding peptide that is recognized and bound by the
corresponding recognition sequence on the virus.
Beyond these variables, the affinity of the virus for the protein may also
be endogenous to the virus or the result of a manipulation of the genetic
make-up of the virus (e.g., such as by way of introduction of an epitopic
peptide present on the surface of a coat protein of the virus). A
preferred way in which to prepare a chimeric virus with which to practice
various embodiments of the present invention is as follows. A sequence of
short peptide ligand (e.g., generally of from 5 to 12 amino acids in
length) with affinity directly to the protein or small molecule of
interest is selected. A fusion near the 3'-end part of the coat
protein-coding region with the sequence of short peptide ligand is made.
TMV particles bearing on the surface epitope tags that are recognized by
the corresponding recombinant protein can be produced. Recognition
peptides of the present invention are not limited to 5-12 amino acids.
They may be longer or even shorter provided that the requisite binding
affinity for the protein or small molecule is maintained for the purposes
of isolation and purification or visualization and localization.
Groups of plant viruses useful in the practice of the present invention
are listed below:
DNA Viruses: Circular dsDNA Viruses: Family: Caulimoviridae, Genus:
Badnavirus, Type species: commelina yellow mottle virus, Genus:
Caulimovirus, Type species: cauliflower mosaic virus, Genus "SbCMV-like
viruses", Type species: Soybean chloroticmottle virus, Genus "CsVMV-like
viruses", Type species: Cassava vein mosaicvirus, Genus "RTBV-like
viruses", Type species: Rice tungro bacilliformvirus, Genus: "Petunia vein
clearing-like viruses", Type species: Petunia vein clearing virus;
Circular ssDNA Viruses: Family: Geminiviridae, Genus: Mastrevirus
(Subgroup I Geminivirus), Type species: maize streak virus, Genus:
Curtovirus (Subgroup II Geminivirus), Type species: beet curly top virus,
Genus: Begomovirus (Subgroup III Geminivirus), Type species: bean golden
mosaic virus;
RNA Viruses:
ssRNA Viruses: Family: Bromoviridae, Genus: Alfamovirus, Type species:
alfalfa mosaic virus, Genus: Ilarvirus, Type species: tobacco streak
virus, Genus: Bromovirus, Type species: brome mosaic virus, Genus:
Cucumovirus, Type species: cucumber mosaic virus;
Family: Closteroviridae, Genus: Closterovirus, Type species: beet yellows
virus, Genus: Crinivirus, Type species: Lettuce infectious yellows virus,
Family: Comoviridae, Genus: Comovirus, Type species: cowpea mosaic virus,
Genus: Fabavirus, Type species: broad bean wilt virus 1, Genus: Nepovirus,
Type species: tobacco ringspot virus;
Family: Potyviridae, Genus: Potyvirus, Type species: potato virus Y,
Genus: Rymovirus, Type species: ryegrass mosaic virus, Genus: Bymovirus,
Type species: barley yellow mosaic virus;
Family: Sequiviridae, Genus: Sequivirus, Type species: parsnip yellow
fleck virus, Genus: Waikavirus, Type species: rice tungro spherical virus;
Family: Tombusviridae, Genus: Camovirus, Type species: carnation mottle
virus, Genus: Dianthovirus, Type species: carnation ringspot virus, Genus:
Machlomovirus, Type species: maize chlorotic mottle virus, Genus:
Necrovirus, Type species: tobacco necrosis virus, Genus: Tombusvirus, Type
species: tomato bushy stunt virus, Unassigned Genera of ssRNA viruses,
Genus: Capillovirus, Type species: apple stem grooving virus;
Genus: Carlavirus, Type species: carnation latent virus; Genus: Enamovirus,
Type species: pea enation mosaic virus,
Genus: Furovirus, Type species: soil-borne wheat mosaic virus, Genus:
Hordeivirus, Type species: barley stripe mosaic virus, Genus: Idaeovirus,
Type species: raspberry bushy dwarf virus;
Genus: Luteovirus, Type species: barley yellow dwarf virus; Genus:
Marafivirus, Type species: maize rayado fino virus; Genus: Potexvirus,
Type species: potato virus X;
Genus: GOTOBUTTON BM.perp. Sobemovirus, Type species: GOTOBUTTON
BM_Southern bean mosaic virus, Genus: Tenuivirus, Type species: rice
stripe virus,
Genus: Tobamovirus, Type species: tobacco mosaic virus,
Genus: Tobravirus, Type species: tobacco rattle virus,
Genus: Trichovirus, Type species: apple chlorotic leaf spot virus; Genus:
Tymovirus, Type species: turnip yellow mosaik virus; Genus: Umbravirus,
Type species: carrot mottle virus; Negative ssRNA Viruses: Order:
Mononegavirales, Family: Rhabdoviridae, Genus: Cytorhabdovirus, Type
Species: lettuce necrotic yellows virus, Genus: Nucleorhabdovirus, Type
species: potato yellow dwarf virus;
Negative ssRNA Viruses: Family: Bunyaviridae, Genus: Tospovirus, Type
species: tomato spotted wilt virus;
dsRNA Viruses: Family: Partitiviridae, Genus: Alphacryptovirus, Type
species: white clover cryptic virus 1, Genus: Betacryptovirus, Type
species: "_white clover cryptic virus 2, Family: "_Reoviridae, Genus:
Fijivirus, Type species: Fiji disease virus, Genus: Phytoreovirus, Type
species: wound tumor virus, Genus: Oryzavirus, Type species: rice ragged
stunt virus;
Unassigned Viruses: GenomessDNA: Species banana bunchy top virus, Species
coconut foliar decay virus, Species subterranean clover stunt virus,
GenomedsDNA, Species cucumber vein yellow virus; GenomedsRNA, Species
tobacco stunt virus,
GenomessRNA, Species Garlic viruses A,B,C,D, Species grapevine fleck
virus, Species maize white line mosaic virus, Species olive latent virus
2, Species ourmia melon virus, Species Pelargonium zonate spot virus;
A variety of animal viruses may also be used. Preferred animal viruses
include retro-, adeno-, adeno-associated viruses, herpes simplex virus and
baculovinises. These viruses have been well studied and characterized so
as to facilitate genetic engineering of the capsid protein (e.g., to
introduce a recognition peptide that directly or indirectly binds the
protein or small molecule of interest).
In embodiments where the protein or small molecule is intended for
administration to or consumption by a human (or other animal), viruses of
plant origin are preferred on account of increased safety and lesser
probability of residual contaminating virus in the final product. Such
viral systems are well described for different plant hosts (for review
see: Porta & Lomonossoff, 1996), insect cell lines, e.g., baculoviral
expression systems for insect cells (Reavi et al., 2000), mammalian cells
(Colosimo et al., 2000).
A preferred embodiment in accordance with the method entails the
production of an exogenous (e.g., heterologous) protein of interest in a
plant host (e.g., plant cells, tissue, homogenate or whole plant). The
embodiment entails providing a plant virus containing a coat protein,
wherein a surface of said coat protein contains a recognition peptide, or
providing a viral expression vector or pro-vector which upon processing
and infection of a plant yields particles of the virus. Another process
step entails genetically modifying e.g., through transient expression or
transfection or stable transformation, the plant host to produce the
protein of interest. A further process step entails infecting the host
with the virus or the viral expression vector pro-vector(s), or otherwise
contacting the host or a lysate or solution thereof with the virus,
whereby particles of the virus form complexes with the protein of interest
via the peptide recognition sequence. Then, particles of the virus having
bound thereto the protein are harvested. The protein of interest can then
be separated from said virus.
In other preferred embodiments of the invention, the tobacco mosaic virus
(TMV) is used to purify to protein made by the plant host. TMV particles
consist of 95% coat protein (2130 copies of the coat protein per virion)
and about 5% of RNA. The weight of one subunit of coat protein (CP) is
17.5 kd and the size of genomic RNA is 6395 nucleotides. The whole size of
the TMV viral particle is about 40000 kd (Creager et al., 1999). It is
very easy to isolate TMV using polyethylene glycol precipitation and
high-speed centrifugation (Turpen and Reinl, 1998). TMV is a very
inexpensive source of protein. In two weeks after inoculation one can
harvest from 2 to 10 g of virus per 1 kg of infected tobacco leaves. In
general, however, the selection of the virus depends upon the type of host
used for the production of the protein (e.g., animal cell, bacterial cell
or yeast cell).
In some embodiments, the virus is a bacteriophage having a coat protein
containing an oligopeptide that recognizes or binds the protein or small
molecule. A phage display system is used to select about a 5-12-mer
oligopeptide with high affinity to the virus being used (for example, TMV).
Several such systems now are commercially available. Phage display is a
selection technique in which a short variable 5-12-mer oligopeptide is
inserted into a coat protein of bacteriophage. The sequence encoding this
variable oligopeptide is included in the corresponding gene of
bacteriophage coat protein. Usually, a 7-mer phage display library has at
least 10.sup.9 independent clones bearing different combinations of 7
amino acids in variable oligopeptides. Phage display has been used to
create affinity complexes between a bacteriophage and a protein of
interest, allowing rapid identification of peptide ligands for a given
target protein by in vitro selection process called "panning" (Parmley &
Smith (1988); Cortese et al. (1995)). The phage-protein complex created
after panning procedure can be dissociated and a phage with affinity to a
target protein can be amplified. Usually, one needs three panning cycles
to get bacteriophage with high affinity. After three rounds, individual
clones can be characterized by sequencing of variable region in genomic
DNA.
Phage display systems have also been developed for identification of small
non-proteinaceous molecule binding sites within proteins and are well
known in the art. (For a review, see: Rodi et al., 2001; Ehrlich et al.,
2000). Such systems have been employed to identify peptides with high
affinity to many drugs such as anti-cancer drugs including paclitaxel
(e.g., taxol) , docetaxel, 2-methoxyestradiol and glycosaminoglycan
hyaluronan. For example, the pentapeptide HTPHP (SEQ ID NO: 1) is known to
have a high affinity for paclitaxel. See (Rodi et al., 1999). This
pentapeptide can be integrated into a viral surface protein as described
herein to isolate taxol from taxol-producing plant tissues. Therapeutic
agents and herbicides are examples of such small molecules. In general,
any non-peptidic organic molecule produced by a host such as a plant,
animal, bacterial or yeast cell, and that is recognizable (e.g., has a
binding affinity for) a peptide may be isolated or detected in accordance
with the present invention. Peptides that bind these molecules may also be
identified using phage display. In general, the small molecules have
molecular weights of from about 250 daltons to about 1,000 daltons.
The virus can be caused to come into contact and bind the protein in the
intact host (e.g., in vivo), such as by infecting the host with the virus
or a viral expression vector. Alternatively, the virus may be contacted
with the protein external to the confines of the host e.g., once the
protein is contained in an homogenate or lysate, such as by affinity
chromatography with viral particles absorbed onto a matrix such as a
column. The conditions employed for dissociating the virus from the
protein (or small molecule) depend on the specific type of interactions
and can be created by varying physico-chemical parameters e.g., pH;
temperature; ions, chelating agents concentration, etc. Selecting
appropriate conditions will be within the level of skill in the art of
protein purification. See, Kent, 1999; Gurgel et al., 2000; Wilchek &
Chaiken, 2000; Muronetz et al., 2001). Ultrafiltration is one such way of
separating protein from virus. In embodiments where the protein is
expressed in the form of a fusion with an affinity peptide that binds the
recognition peptide on the surface of the virus, separation of the protein
is facilitated by the presence of a cleavable linkage between the protein
and its fusion partner. The cleavage sites can be but not limited to those
recognized by enterokinase (Choi et al., 2001) or cyanogen bromide (Assadi-Porter
et al., 2000). Examples of other cleavage sites are trypsin, chymotrypsin,
factor Xa protease and hydroxylamine. Yet another manner of creating a
cleavable fusion with the protein of interest is based on the use of
inteins. See, Chong et al. (1997). This system utilizes a protein-splicing
element termed an intein from yeast in conjunction with an affinity tag.
The modified intein can be induced to undergo self-cleavage at its
N-terminal peptide linkage under certain mild chemical conditions. A
target protein is cloned in-frame with the N-terminus of the intein-affinity
tag fusion. The immobilized fusion protein is then induced to undergo
self-cleavage under mild conditions (which does not require proteolytic
cleavage), resulting in the release of the target protein while the intein-affinity
tag remains bound to a column (Cantor & Chang, 2001). Thus, in the present
invention, the transgene introduced into the host expresses the protein in
the form of a fusion with an intein based cleavable affinity tags that
bind to the viral surface.
This invention is suitable for the purification of transgenic and
endogenous proteins alike as well as non-proteinaceous molecules occurring
naturally or as a consequence of transgene expression in wide variety of
hosts including but not limited to members of the plant, animal and
bacterial kingdoms. Examples of such proteins can be, but not limited to
pharmaceutically and industrially important proteins, e.g. immune response
proteins, enzymes including DNA modifying enzymes, starch-, cell wall
modifying enzymes, proteases, lipases etc.
In the case of proteins or small molecules that are exogenous to the host,
transgenes encoding the protein (by itself or in the form of a fusion with
a peptide that binds the recognition peptide on the virus) or the
expression of which result in the production of the small molecule, are
introduced into a non-human host in accordance with standard techniques.
In general, these techniques include stable or transient transformation or
by way of viral delivery (e.g., infection of the cell by the viral
expression vector). Methods of creating transgenic organisms with stably
integrated foreign genes are well described in the literature. For
example, DNA can be transformed into plant cells via Agrobacterium-mediated
delivery. See, U.S. Pat. Nos.: 5,591,616; 4,940,838; and 5,464,763. Other
methods include particle or microprojectile bombardment (U.S. Pat. No.
5,100,792; European Patent (EP) 444,882 B1; EP 434,616 B1), microinjection
(WO 09209696; WO 09400583 A1; EP 175,966 B1) and electroporation (EP
564,595 B1; EP 290,395 B1; WO 08706614 A1). Procedures of transgene
delivery into animal, bacterial and yeast cells are well established. A
popular method of transgene delivery into animal cells is
retrovirus-mediated (Robbins & Givizzani, 1998; Reynolds et al., 1999).
Other methods with synthetic (non-viral) carriers are also suitable (for
review see: Bown et al., 2001). Transformation methods for yeast and
bacterial cells are well described in many manuals e.g., Yeast Protocol
Handbook (2000) and Sambrook et al., (1989).
The present invention is amenable to industrial application and scaling-up
because it can accommodate techniques such as tissue homogenization,
centrifugation and ultrafiltration. It can be applied to production of
proteins and small molecules in any prokaryotic or eukaryotic system.
Thus, the invention will allow development of a universal, inexpensive and
easily scale-up method of purification of any protein of interest from any
kind of prokaryotic or eukaryotic system designed for protein production.
The use of viral particles provides an inexpensive source of homogenous
protein (coat protein), which at the same time is easily genetically
modified. Another key advantage of this invention is the ability to use
epitopes to identify an oligopeptide with high affinity to the target
protein. By incorporating the epitope into the viral coat protein as the
surrogate affinity matrix fusion, the protein or small molecule of
interest may be isolated without any modification and without the need for
any subsequent cleavage step. As result, an intact protein of interest is
produced. The fact that viral particles are significantly larger than even
the largest protein (about 40000 kD vs. a maximum 300 kD), allows
efficient separation of the protein of interest from the viral particles
by simple ultrafiltration.
The virus purification tag systems of the present invention are also used
for localization or detection of proteins on the surface or in different
compartments of cells. Immunostaining with gold-labeled antibody is widely
applied for solution of such experimental tasks (Milne RG, 1993). Another
approach in this field is the use of gold-labeled streptavidin (Prendes et
al., 1999). The method of the present invention entails visualizing or
localizing a protein or non-proteinaceous small molecule of interest,
comprising: (a) providing a virus having affinity for the protein or small
molecule and an affinity for a visualization agent; (b) obtaining a host
that produces the protein or small molecule of interest; (c) contacting
the host or a preparation thereof with the virus;
(d) exposing the thus-contacted host or preparation thereof with the
visualization agent; and (e) detecting presence or locale of the protein
or small molecule. In this aspect of the present invention, the virus
functions as a matrix providing a large number of interaction sites for
amplification of a signal that can be detected by standard techniques such
as immunological-based methods (e.g., ELISA) and electron microscopy (e.g.
labeling with gold). Selecting naturally occurring viruses or genetically
engineering viruses that recognize or bind various proteins or small
molecules are well within the level of skill in the art. In addition,
chimeric viruses can be made that recognize both the protein/small
molecule and a visualization agent. For example, chimeric TMV particles
are produced by in vitro self-assembly. To localize a protein in a host
(e.g., a cell surface protein), a phage display system is used to identify
an epitope tag such as a heptapeptide that recognizes that protein. A
fused TMV CP (coat protein) containing this epitope tag near the carboxyl
end of the protein is then created. The virus is further engineered to
contain a CP-bearing epitope tag recognizing streptavidin such that when
self-assembled in vitro, chimeric virus protein particles bearing both
epitope tags are generated. To localize the position of the protein, the
chimeric self-assembled TMV particles are combined with the host as is
done in accordance with techniques involving antibodies described in the
prior art. The cell-TMV complex is then incubated with a detectably
labeled (e.g., gold-labeled) streptavidin. Electron microscope analysis
shows localization of the protein by both very specific rod-shaped TMV
particles and black spots of gold-label. Plainly, a variety of
visualization or localization agents e.g., detectable labels and physical
agents (e.g., ultraviolet light, fluorescent agents, enzymatic activity
causing substrate visualization--identical to those being used in Western
blot systems) may be used depending on the detection mechanism employed.
Claim 1 of 27 Claims
1. A method of purifying a protein or
non-proteinaceous small molecule of interest, comprising: (a) providing a
plant virus having on its surface at least one recognition peptide, or
preparing a plant viral expression vector which upon infection of an
organism yields particles of the virus, wherein said virus or viral
expression vector is genetically modified to produce said recognition
peptide; (b) obtaining a host that produces the protein or small molecule
of interest independent from or due to presence of the virus therein; and
(c) infecting the host with the virus or the viral expression vector
whereby particles of the virus form complexes with the protein or small
molecule via the peptide recognition sequence, followed by harvesting the
complexes of the virus and protein from the host, or contacting a lysate
or solution of the host with the virus, whereby particles of the virus
form complexes with the protein or small molecule via the peptide
recognition sequence, and the protein or small molecule is separated from
the solution. ____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|